PMID: 16613664Apr 15, 2006Paper

Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer

The Cancer Journal
Abdelkarim S AllalNicolas Mach

Abstract

This study was conducted to determine the maximum tolerated dose of docetaxel when administered concomitantly with radical hyperfractionated radiotherapy and cisplatin in patients with locally advanced head and neck cancer. Patients with stage III-IV tumors received radical radiotherapy of 74.4 Gy given in two daily fractions of 1.2 Gy for 6 weeks. Cisplatin was given once weekly on day 1 at a constant dose of 15 mg/m2. The starting dose of docetaxel was 10 mg/m2 once weekly on day 3, with planned escalation steps of 5 mg/m2. Main endpoints of the study were the maximum tolerated dose of docetaxel, acute toxicities, and the preliminary efficacy results. Twenty-five patients were enrolled. Median follow-up was 15 months (range: 4-40 months). Two of three patients presented with dose-limiting toxicities at the 15-mg/m2 dose of docetaxel (one patient presented with multiple grade 3-4 toxicities requiring hospitalization for management and another presented with multiple toxicities including life-threatening bronchoaspiration). Thus, the weekly docetaxel dose of 10 mg/m2 was considered the maximum tolerated dose. Nineteen patients were then treated with the maximum tolerated dose and no dose-limiting toxicities were observed. Radio...Continue Reading

References

Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J C HoriotM Bolla
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S El-Sayed, N Nelson
Mar 20, 1998·The New England Journal of Medicine·J I VaughanI A Roberts
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B JeremicL Tadic
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everett E VokesDaniel J Haraf
Mar 30, 2004·Bulletin du cancer·Gilles Calais
Apr 27, 2004·International Journal of Clinical Oncology·Masato FujiiUNKNOWN Japan Cooperative Head and Neck Oncology Group (JCHNOG)
Oct 7, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN American Society of Clinical Oncology
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pia HugueninChristoph Glanzmann

❮ Previous
Next ❯

Citations

Sep 16, 2008·Molecular Cancer Therapeutics·Erica L Bradshaw-PierceDaniel L Gustafson
Apr 16, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Agustí BarnadasAntonio Arellano
Oct 23, 2008·Physical Medicine and Rehabilitation Clinics of North America·Barbara R Pauloski
Feb 10, 2007·International Journal of Radiation Oncology, Biology, Physics·Christopher D WilleyAnthony J Cmelak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.